NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

August 09, 2005 13:54 ET

Nymox NicAlert™ Will be Used in Nevada Tobacco Free Babies Program

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Aug 9, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company's NicAlert™ product will be used in routine assessment as part of the Tobacco Free Babies Program at the Washoe Pregnancy Center in Reno, Nevada. The Program is funded by the State of Nevada and includes tobacco dependence interventions and referrals to the Nevada Tobacco Users Helpline for cessation and exposure reduction.

The Program Manager, Dr. Sher Todd said, "A major objective of this program is to ensure that tobacco exposure assessment and counseling become assessed as a vital sign."

Nymox's NicAlert™ product provides a proven, easy-to-use, on-site means of determining an individual's use of or exposure to tobacco products. The product gives a visual read-out of the level of tobacco use or exposure within minutes and requires no instruments to use. NicAlert™ has received U.S. FDA clearance for medical use for determining an individual's exposure to tobacco products.

NicAlert™ uses powerful, one-step patented technology to measure the level of cotinine, a metabolite of nicotine, in urine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product use or exposure. NicAlert™ testing can be performed almost anywhere, including at home, the workplace or school.

Nymox also offers TobacAlert™, which is for non-medical uses and can detect second-hand smoke exposure. TobacAlert™ is available at approximately 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information about TobacAlert™ is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com